Education
About Us
Working with TipRanks
Follow Us
VFLO - ETF AI Analysis
Top Page
VictoryShares Free Cash Flow ETF (VFLO)
Rating:75Outperform
Price Target:―
Positive Factors
Strong Cash-Generating Focus
The ETF targets companies with solid free cash flow, which can support more stable business operations and potential shareholder returns over time.
Resilient Top Holdings
Several of the largest positions, such as Merck, Chevron, Newmont, Accenture, Amgen, Devon Energy, and Royalty Pharma, have shown generally strong or steady performance, helping support the fund despite recent market softness.
Broad Sector Mix
Holdings spread across technology, energy, health care, consumer, industrials, and other sectors help reduce the impact of weakness in any single industry.
Negative Factors
Recent Performance Weakness
The ETF has slipped over the past month and is slightly negative so far this year, which may concern investors looking for near-term strength.
High U.S. Concentration
With almost all assets in U.S. companies, the fund offers little geographic diversification and is heavily tied to the U.S. market’s fortunes.
Moderate Expense Ratio
The fund’s fee is higher than many broad, low-cost index ETFs, which can slightly reduce long-term returns for buy-and-hold investors.
VFLO vs. SPDR S&P 500 ETF (SPY)
AUM6.17B
RegionNorth America
Expense Ratio0.39%
Beta0.80
IssuerVictoryShares
Inception DateJun 21, 2023
Dividend Yield1.43%
Asset ClassEquity
Index TrackedVictory US Large Cap Free Cash Flow Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,242,221
30 Day Avg. Volume1,186,552
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
46.52Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VFLO Summary
VictoryShares Free Cash Flow ETF (VFLO) is a fund that follows the Victory US Large Cap Free Cash Flow Index, focusing on big U.S. companies that generate strong extra cash after paying their bills. It holds a mix of sectors like technology, energy, and health care, with well-known names such as Merck and Chevron among its top holdings. Investors might consider VFLO for diversified exposure to financially solid, established companies that may offer more stable growth over time. However, the ETF can still go up and down with the overall stock market, and it is heavily tilted toward U.S. large-cap stocks.
How much will it cost me?The VictoryShares Free Cash Flow ETF (VFLO) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on companies with strong free cash flow to potentially enhance returns. It’s designed to offer strategic exposure to large-cap stocks with robust financial health.
What would affect this ETF?VictoryShares Free Cash Flow ETF (VFLO) could benefit from strong performance in the technology and energy sectors, which make up a significant portion of its holdings, especially if innovation and global energy demand continue to grow. However, economic challenges like rising interest rates or regulatory changes in healthcare and energy industries could negatively impact some of its top holdings, such as Merck, Exxon Mobil, and Chevron. Additionally, its focus on U.S. large-cap companies means it is sensitive to domestic economic conditions and policy shifts.
VFLO Top 10 Holdings
VFLO is leaning heavily on U.S. energy and health care names, and that’s where most of the action is. Chevron, Devon Energy, Diamondback, and Coterra have been rising together, giving the fund a strong tailwind from the oil patch, while Newmont adds an extra boost from the materials side. On the health care front, Merck and Amgen are steady leaders, with Royalty Pharma quietly pulling its weight as well. Cigna looks more mixed and isn’t really moving the needle, and Zoom is more of a side character than a star in this story.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Merck & Company | 4.75% | $292.84M | $286.57B | 22.38% | 80 Outperform | |
| Chevron | 4.18% | $257.78M | $393.03B | 28.23% | 71 Outperform | |
| Cigna | 3.97% | $244.34M | $70.07B | -14.78% | 72 Outperform | |
| Devon Energy | 3.45% | $212.71M | $28.64B | 36.70% | 79 Outperform | |
| Newmont Mining | 3.20% | $197.32M | $124.54B | 150.78% | 81 Outperform | |
| Diamondback | 3.19% | $196.26M | $49.79B | 21.41% | 81 Outperform | |
| Royalty Pharma | 3.18% | $195.82M | $26.46B | 40.36% | 79 Outperform | |
| Amgen | 3.10% | $190.76M | $198.26B | 17.64% | 77 Outperform | |
| Valero Energy | 2.94% | $181.41M | $70.51B | 87.45% | 69 Neutral | |
| Coterra Energy | 2.91% | $179.10M | $24.28B | 19.68% | 73 Outperform |
VFLO Technical Analysis
Neutral
―
Price Trends
39.90
Negative
39.15
Positive
37.45
Positive
Market Momentum
-0.09
Positive
40.17
Neutral
10.83
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VFLO, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 40.00, equal to the 50-day MA of 39.90, and equal to the 200-day MA of 37.45, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 40.17 is Neutral, neither overbought nor oversold. The STOCH value of 10.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VFLO.
VFLO Peer Comparison
Comparison Results
Performance Comparison
VFLO
VictoryShares Free Cash Flow ETF
39.20
5.62
16.74%
MGC
Vanguard Mega Cap ETF
―
―
―
QQQI
NEOS Nasdaq 100 High Income ETF
―
―
―
PRF
Invesco FTSE RAFI US 1000 ETF
―
―
―
RWL
Invesco S&P 500 Revenue ETF
―
―
―
QYLD
Global X NASDAQ 100 Covered Call ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents